Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

612
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
612
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.6K
3.6K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

598
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
598
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

373
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
373
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

338
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations for Pre-Analytical Urine Sample Handling To Allow Optimal Assessment of Albuminuria and Proteinuria A consensus report of the USA NKF Albuminuria - Proteinuria Workshop.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023.

Kidney international·2025
Same author

Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop.

Glomerular diseases·2025
Same author

Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.

Kidney international·2025
Same author

Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2024

Related Experiment Video

Updated: Jan 25, 2026

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
10:51

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

Published on: December 2, 2014

11.5K

ICD-10 codes for APOL1-mediated kidney disease.

Barry I Freedman1, Barbara S Gillespie2, Ogo I Egbuna3

  • 1Department of Internal Medicine, Section on Nephrology; Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Kidney International
|January 23, 2026
PubMed
Summary

New ICD-10-CM codes for APOL1-mediated kidney disease (AMKD) aid diagnosis in individuals of African ancestry. These codes improve patient classification and advance research for better treatments and earlier detection of AMKD.

Keywords:
APOL1African ancestryFSGSICD codechronic kidney diseaseepidemiology

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.5K

Related Experiment Videos

Last Updated: Jan 25, 2026

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
10:51

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

Published on: December 2, 2014

11.5K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.5K

Area of Science:

  • Nephrology
  • Genetics
  • Public Health

Background:

  • APOL1-mediated kidney disease (AMKD) affects millions globally, particularly those of African ancestry.
  • Previous diagnostic codes were often vague, leading to misclassification and hindering epidemiological studies.
  • Lack of specific AMKD codes in major registries impacted public health research and treatment development.

Purpose of the Study:

  • Introduce new International Classification of Disease-10th Edition-Clinical Modification (ICD-10-CM) codes for AMKD and family history of AMKD.
  • Improve diagnostic accuracy and patient identification for AMKD.
  • Facilitate better research and clinical trial enrollment for AMKD.

Main Methods:

  • Implementation of new ICD-10-CM diagnostic codes in the United States.
  • Emphasis on vigilance by nephrologists and healthcare providers for patient identification and genotyping.
  • Integration of AMKD coding into national and international health data systems.

Main Results:

  • Enhanced ability to accurately classify patients with AMKD, especially nondiabetic individuals of African ancestry.
  • Potential to correct misclassification issues in existing patient datasets.
  • Foundation for more precise epidemiological studies of kidney failure.

Conclusions:

  • The new ICD-10-CM codes represent a significant advancement for AMKD diagnosis and management.
  • Healthcare providers must actively identify, genotype, and code patients with AMKD.
  • Earlier detection through improved coding will enable enrollment in clinical trials, offering hope for cures.